# Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 Canonical URL: https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-host-virtual-kol-investor-event-to-review-ampreloxetine-phase-3-clinical-development-program-ahead-of-topline-data-in-q1-2026-on-december-8-2025 Ticker: TBPH Company: Theravance Biopharma Source: Theravance Biopharma Published: 2025-11-20 16:00 EST Original Source URL: https://investor.theravance.com ## Summary DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET . To register, click here .     The event will feature Horacio Kaufmann , MD (Dysautonomia ## Article Body DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET . To register, click here . The event will feature Horacio Kaufmann , MD (Dysautonomia ## Recent Company News - 2026-05-07 12:30 EST — [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma - 2026-03-19 12:30 EST — [Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma - 2026-03-03 13:30 EST — [Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions](https://biopharmsignal.com/news/TBPH/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet-primary-endpoint-board-accelerates-strategic-review-and-announces-cost-reduction-actions) — Source: Theravance Biopharma - 2025-11-20 16:00 EST — [Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-host-virtual-kol-investor-event-to-review-ampreloxetine-phase-3-clinical-development-program-ahead-of-topline-data-in-q1-2026-on-december-8-2025) — Source: Theravance Biopharma - 2025-11-19 11:00 EST — [Theravance Biopharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-participate-in-upcoming-investor-conferences) — Source: Theravance Biopharma ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)